Adrian our that you, as good I a company. mission thank medical for and are joining to Thank report our continue and they Hey. and making progress PAVmed long-term you subsidiaries call. technology diversified update happy leading and to create quarterly its everyone driving afternoon, am solid
long-term like commitment. support ongoing would to I your thank our proceeding, shareholders for Before and
over combined has growing enhancing is employees and team Our shareholder grown the to focused XXX value. enterprise, on singularly long-term while PAVmed
us Our with execute providing the strategy. to balance this remains sheet resources strong
efficiently cash opening to Given of market the we goals and as to pass current start baton deploying like are our over and to our focused provide plus will update will before possible Dennis who runway. to providing as I’d our by financial an it particularly the our then extending volatility, and questions. on accomplish business strategic overview capital up effectively reserving our
medical device, PAVmed diversified operating medical technology the and stage First in a digital some commercial diagnostics on background PAVmed. sectors. health is company
mission save Our by to quality, solutions, enhancing service effectiveness. the is or while which and and cost lives efficiency improve patients and healthcare to disruptive and providing significantly technologies products utilize state-of-the-art innovative
three and XX% listed monitoring. care a business pipeline owns value laser-focused design subsidiaries various which commercialization its Lucid of and of its through company R&D development, the evidence shared Veris Health remote for only early PAVmed economies to The developing R&D cancer NextFlo benefits of profitable medical intelligent are the to growing owned mute at today widespread cost an markets Thank engine digital team. other stages leader precancer as majority of business and These affairs. development, capital and services units broad implantable who through of outstanding owns or personalized range to shares. administration you of the approximately potential. general the approximately EsoCheck, of research, the in esophageal of on central through test. and provides as clinical could all consists subsidiary a operates product PAVmed medical esophageal precancer shares. biologic including Veris’ company, the Veris greater commercial quality product participants Health, business with commercial products the a regulatory port of shared CarpX vascular health products. affairs, which PAVmed two units, communication units of enterprise first for of through XX% is and the development. as prevention to outstanding NASDAQ Lucid’s finance, and centralized diagnostics stage clinical facilitate Diagnostics to model improve two tools and and manufacturing This build line? vision detection creation – well each provides EsoGuard management, Lucid and is lower its and subsidiaries prevent risk the and first include PAVmed and scale sectors. access the sensors allows wireless major each services patient is technology Our and across cancer a and you. Operator, diversification numerous across model be The much diversified mitigation growth enterprise medical subsidiaries
mostly execution, entirely believe laying is of now and We in During success, are as we years. optimizing infrastructure our the expanded essentially as revenue commercial coming and quarters foundation and XXXX, on couple years, expanding and The the have on reimbursement in undergone is internal human focused place and growth we the focusing systems expansion transition transition physical well this for especially a in past major our rationalizing complete. infrastructure portfolio. and commercial
I listen read to Adrian and updated with contact ACG commercialization, additional guidelines, E which call operations for on starting Lucid units or to you distillation of the details feel and recording free My be discussion a with reimbursement. help the call EsoGuard laboratory with the transcript and of a the of would proceed Lucid pipeline with the to yesterday's to my business. Lucid remarks during subsidiaries Now focus will an this. update dominant business Lucid, remains encourage PAVmed's of R&D
updated American on the diagnosis recently announced, XXXX. the management guideline the Gastroenterology first since previously its esophageal update we of of such and clinical precancer, College as So
an biomarker and EsoCheck, an screening overemphasize non-endoscopic invasive the are I time test. This efforts as guideline acceptable currently biomarker For development is esophageal it’s for the in only eradicate which and as costly the alternative screening an important endorse nonendoscopic cancer. and our such can described EsoGuard endoscopy. supporting exciting in to the guideline I alternative Lucid first to
well. efforts commercialization EsoGuard going Our are
quarter nearly volume. see We the increase of We fourth in robust excellent XXXX, from EsoGuard tests surgeon XXX XXXX. that XX% continue a primary to of growth volume XXXX the processed in first strong to centers sequential of Testing testing physician performed our referrals as XXX% in and test both channels was with well practices sales quarter institutions. at increase EsoGuard first commercial as specialty represents foregut annually a traction from growth quarter gastroenterology, test care and the Lucid
and sales to investing full infrastructure transition and efforts. clinical utility generate drive testing is revenue established, demonstrate reimbursement we Once to claims are growth. our throttle will in support We sufficient reimbursement efforts volume to to more fully
have operating hitting as of Our reps continues six sales our managers months team development operation of to staff. we within and are three about now of sales VP And XX consists effectively sales market and to four a as new targets hiring several seek well reps, Sales, hiring. grow Directors, Area and National
oversee primary Lucid facility support primary The modest variable in covers patients western entirely test Director marginal where margins our additional undergo XXXX businesses. the physicians by month, Collection this Test cost first stage dialysis very Cell during year. Centers centers U.S. Center care procedure. hired The operating Lucid the have expansion. seven plan Our facilities a Clinical stage-X the expanding Test open now by states Last EsoGuard providing recently to network we quarter centers first launched program. and test as its We at experience our cities. extensive attractive and channel testing Services referred operating for program can of completed We with a care EsoCheck Lucid cost almost of Test Center of nine of to
which pilot telemedicine continue do our also We launched EsoGuard in of December. the program we
the are the strategy actively telemedicine I program, we pursuing in basis patients a advertising only with Test city previously limited described. direct-to-consumer any can consistent Center near-term on pilot in Phoenix, Although Lucid that access
will of a the upgraded Claims acquired Lucid took Last and and over and California. have laboratory operate we provider the fully of Lucid our subsidiary first the future new operations, accelerate the employees. been getting of to to of agreement experience, the clinical own full cycle At to we are to month, time license the the program VP decades the for services line. revenue the be CAP-accredited In quarter transfers awaiting entity hold of submissions CLIA-certified, parallel a assets company. been new Orange new staffed months in testing. with first and necessary leadership the critical have directly transition success the and plan to laboratory end in wholly-owned EsoGuard being for two which billing The Labs, clinical from Lucid our Diagnostics the with billing developments acquisition, current of nearly County, the a important lab Laboratory on first billing a since the – Operations for by management on February, DX hired we laboratory we recent Lucid management laboratory
revenues in will from out will Dennis as laboratory from temporary our describe network more a billing recognize transition direct result the monthly detail. fixed former So to and payments pause receipts of in partner in
a update reimbursement. Now, on brief stand with where we
DX we utility approximately $X,XXX. effective payer which of through over that to the decision-making, national On to lives The for based first coverage Medicare secure and in-network commercial for X collect our parallel, list national medical $X,XXX agreement just executed payment direct a provider which under positively a In multi-specialty network Lucid is of consistent payers. payer into a provider protecting Health Labs with demonstrating effective critical of Plans, us contract the PPO agreement, health data plans. over and participating EsoGuard contracted private our regional on is clinical its impact necessary with with we clients EsoGuard from price goal this directly continue side, is MediNcrease entered payment million covered
screening. to Medicare next tests The pre-cancer the not We the expects final to an XXXX. the our patiently important testing, and MolDx esophageal Foundational recommendation the acceptable to Last EsoGuard supporting non-endoscopic triggered received period pre-cancer front. The and have back the on guideline, cancer. take contractor, written to the a test proposed modifications open LCD. We’ve pre-cancer of LCD in the provisional along updated comment other important ACG consideration publication cancer with proposed progress molecular gastrointestinal also Local extends prior address publication as been be of into meet. designed MolDx month, LCD. we proposed published and a interested January Palmetto LCD the with and Saturday. upper as proposed Determination, until such does reimbursement Medicare a endoscopy that the alternative biomarker GI as other program that upper determination payment such emphasize stakeholders outlines days for we was detect two proposed multiple Medicare of this MolDx We published that since had criteria It’s to also meeting ago LCD to suggesting will during to along parties and process comments diagnostic important which this LCD step stakeholders held awaiting or GBA’s the for opportunity Coverage seen substantive submitting
meeting have to We has In scheduled LucidDX comment Labs as will that LCD Healthcare final participates and not that through proposed opportunity be look the XX. May Solutions, extends contractor well. comments. A Medicare which covers the the program open the to issued a the June addition, contractors assess in recently in learned opportunity had the XX LCD its Medicare until and own and written address period Meridian these consider MolDx on Meridian to forward with directly we
clinical value predict capable substantial continuous prospects data, physiologic and of undergoing cancer on patient's and healthcare parameters Veris sector reporting PAVmed's on digital adverse is designed machine device, outcomes cancer-related and tools allow data-driven existing of complications, clinical remote board. function a trial and launched effectively which digital of to platform an health precision symptom Now learning. analytics. and smartphone subsidiary biologic world-class Veris are patient ago data Veris with implantable reimbursement offer that is "smart foray was connected sensors biotherapeutic health longitudinal a trends on and common Veris telehealth of communication model focus management monetization physiologic data cloud-based for risk let's revolution, deliver and Technology support. known to a Wireless midst The an that oncology sector leverages monitoring. year integrates and a dynamic to rapidly the to based including its first owned early data Health. intense and patients creation contains medical physiologic key is oncologists incorporate data the the generating and for treatment. as move other physicians. platform The patients is and detect device developing includes through analytics three to care devices" additional our data into technology Veris The intelligence real-time data growing with digital codes the in mission help Veris service will of is software, on provide advanced advancing signs that remote sensing, its technology the for intelligent fronts, vascular advisory to of actionable and and business access artificial with efficiently cancer on software technology Software-as-a-Subscription majority
We partner program. its as very working Microsoft closely member global also are with of a
Our further Chief the late has look launch Microsoft productive Commercial The extensive in in a headquarters team very commercial year. we our major first team of a anticipation this anticipation first hired forward what commercial We’ve next Veris Officer relationship. growing and Veris launch strengthening in to sector. to this actually with week traveling is been oncology to is experience
across and We will are including to we establish as I enterprise our out and machine PAVmed data that available analytics genomic data team research shared be note consistent hires the with our expertise should expertise analytics with including analysis future using four the also in-house seek an strong model, and data and exciting intelligence services artificial learning. generations. new building
communicate for data its care On uploads team clinical a with and on to oncology device, App implantable interconnected to software which the data and with the facilitate the excellent progress making to with platforms, a the platform provides monitoring cloud-based patient the the patient patient software App software intelligent the front, remotely. a we're engage team the to smartphone platform three App cloud-based namely, smartphone designed
allow give software devices. will product valuable us connected As the previously to existing Veris this into have landscape. get and with platform commercial medical opportunity designed I us launch platform experience the What early three wearable noted, and This with initial the to referring we Solar the we're work software and to first as real-world navigate adopters. combines the effectively best with split engage regulatory parallel projects to
our on port. to Solar schedule leverage a proceed device. implantable By to be this biosensing We on alongside will expect FDA's Veris as implantable The and are the later port, happy the of and the the own include development Very implanted XXXK able predicate the on adds path. device be monitoring that device features smart year. separate we contemplated, existing launch generation will separating mercury with all Mercury. Veris traditional design be will monitors to progress the from Veris down but device the a first to-date
in XXXX. coming prototypes the targeting are latest scheduled in submission we and and animal second weeks the a lab launch have test We to
vascular me. will intelligent fully of as Venus the Venus many the offer port Veris access Finally, components Mercury, utilizing – Mercury same excuse integrated
development to it about to we Veris battery integrated need much through smaller how doesn’t features really Europe We very access work with stemming advance FDA's predicted – fully ECG The allow form multi-year be novo up. for will for the factor will device point. recording to device Venus is be the will and achieve the first less EU device progressing design are excited project because product Veris onerous well, this and de able a integrated pathway, mimic seek also regulations intelligent of to Mercury need classic the but and will the full the is a strategy vascular could this on on
device Let's our ago. really is six major are tunnel early to our invasive limited There release, treat continues syndrome. CarpX. XXXK call move no on CarpX leaders. from with FDA weeks now minimal key adopter carpal its opinion cleared updates to CarpX commercial utilizing
that we on to-date. clinical I then, from explained implemented experience U.S. while surgeons we the cases of As were product hold had derived improvements
electrode product on improvements have of set completed addressing product and including now manufacturing recently first just have issue The commercial back we an shelf. coating been the
scheduling training are labs cadaver with and this restarted have trained cohort surgeons. cases We of
device subsequent FDA the the As submission XXXX. a that CarpX later incorporates development product next-generation ultrasound And slated expand also which – be improvements introduced we is at that imaging last this are point noted, should a completed broadly. well be previously position call target integrated the to can more year, with as in I in during of progressing commercialization last
NextFlo. on to So
infusion platform a is technology. NextFlo
to our the by of each need is in seeks for The complex, electronic prone error incorporating infusions it day. million most first intravenous country NextFlo for the which performed this expensive care pumps eliminating and product set, revolutionize one infusion
I team The FDA and have better call, will main comprehensive a flow on successful R&D other that a a of traction intraosseous ago. just targets. of in six study device. redesign to have implantable options Columbia, been it on And require we products reinitiated Three will long-term midst is impact the but in begin not redesign. data is FDA for the Once first As submission the new – first pipeline. flow good at short patients human South call is will in pre-DDV last noted a addressing to our next small repeatability recog and understanding month. is of regulation, and the that midst America commercialization. is issue in regulator demonstrated PortIO we flushing Not analysis our and vascular our small had update trained access good since submission last approved since this the enrolling does comments repeatability a testing Pre-DDV device. improve through prior sites fell site. timelines work reports believe weeks four exploring be clinical complete, one our with maintenance-free how access repeatability. PortIO, in implants which in its lot vascular key a additional few the PortIO, after We of
US We support data are also to and additional Europe to working clearance with European partners provide a mark study for EU human CE our in pursue approval.
favorably Barrick is the Based and we response dose treat progressing is to on Our development. completed studies is to also the to-date, focused Medtronic’s endoscopically histology device EsoCure market-leading design well. designed animal and the thereof, esophageal and work on chronic compares head-to-head precancer optimizing EsoCure device. Current believe
Finally, discussions to the smart we Excuse development an continue update opportunities pushing opportunities updates before provide as flush space to have business will especially on the proceeding Dennis provide to more we’ll our questions. Dennis? me. into active with – before hand reins the a on on and on that, out. I With comprehensive device financial
